

DATE OF AGM AND CLOSING DATE FOR DIRECTOR NOMINATIONS

Perth, Australia; 16 September 2022 – Argenica Therapeutics Limited (Argenica or Company) (ASX: AGN) advises, in accordance with ASX Listing Rule 3.13.1, that its Annual General Meeting (AGM) will be held on Thursday, 24 November 2022.

The location of the meeting and details of all resolutions to be considered at the AGM will be contained in a Notice of AGM and Explanatory Memorandum which will be dispatched to shareholders prior to the meeting.

In accordance with the Company's constitution, any person wishing to be considered for election as a director of the Company must submit a nomination which must be received at the Company's registered office no later than Thursday, 6 October 2022.

This announcement has been approved for release by the Company Secretary

For more information please contact: info@argenica.com.au

ABOUT ARGENICA

Argenica (ASX: AGN) is developing novel therapeutics to reduce brain tissue death after stroke and improve patient outcomes. Our lead neuroprotective peptide candidate, ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicity before commencing Phase 1 clinical trials in humans. The aim is for our therapeutic to be administered by first responders to protect brain tissue against damage during a stroke with further potential to enhance recovery once a stroke has taken place.